On ECHEMI
Home > Drugs > Thrombocytopenic purpura
Thrombocytopenic purpura
Thrombocytopenic purpura is caused by thrombocytopenia, which leads to petechiae, ecchymoses or internal bleeding on the skin and mucous membranes. It is divided into primary or idiopathic thrombocytopenic purpura and secondary or symptomatic thrombocytopenic purpura.
  • Site of disease:

    Skin blood vessels
  • Infectious :

    Not contagious
  • Frequent population:

    More common in women
  • Related symptoms:

    With skin and mucous membrane bleeding repeated epistaxis negative urine bilirubin skin and mucous membrane bleeding skin bleeding spots
  • Concurrent disease:

Related Drugs
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura and Kawasaki disease.
Manufacturer:

Shenzhen Weiguang Biological Products Co., Ltd.

Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura and Kawasaki disease.
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura, Kawasaki disease.
Manufacturer:

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

PREDNISONE TABLETS, USP, 5 MG- prednisone_tablet
Indication: INDICATIONS AND USAGE
Prednisone tablets are indicated in the following conditions: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Acute exacerbations of multiple sclerosis Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement.
Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis
Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis
Dermatologic Diseases
Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions
Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis
Respiratory Diseases
Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis
Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia
Neoplastic Diseases
For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood
Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Acute exacerbations of multiple sclerosis.
Multiple Sclerosis
In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.)
Manufacturer:

PREDNISONE TABLETS, USP, 10 MG- prednisone_tablet

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.